Skip to content

Anavex Life (AVXL) Stock Rallied 67.3% After Trial Met Endpoints

Simon Mugo trader
Updated 2 Dec 2022

The Anavex Life Sciences Corp (NASDAQ: AVXL) stock price rallied 67.3% after releasing the phase 2b/3 clinical trial of its oral ANAVEX®2-73 (blarcamesine) for the treatment of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD (collectively known as early AD).

new-recommended-broker-banner

YOUR CAPITAL IS AT RISK. 81% OF RETAIL CFD ACCOUNTS LOSE MONEY.


ANAVEX®2-73 met its primary endpoints and critical secondary endpoint with statistically significant results. The clinical-stage company expressed its intention to meet with regulators in the U.S., Asia Pacific and Europe to make the treatment available to AD patients in these regions.

Top Broker Recommendation

YOUR CAPITAL IS AT RISK. 68% OF RETAIL CFD ACCOUNTS LOSE MONEY

The data from the clinical trials suggest that ANAVEX®2-73 (blarcamesine) could be crucial to promoting neural and restoring neural cell homeostasis in patients with Alzheimer’s. 

The ANAVEX®2-73-AD-004 trial was a randomized, double-blind, multicenter, placebo-controlled clinical study that enrolled 509 patients with early-onset Alzheimer’s disease over 48 weeks. The patients received mid to high doses of a placebo or ANAVEX®2-73. 

The data released yesterday was the topline data, which was presented at the Clinical Trials on Alzheimer’s Disease (CTAD) Congress 2022, December 1, 2022, at 4:30 pm PT in San Francisco, CA.

Anavex Life Sciences is currently analysing the data collected from the clinical trial with the ultimate goal of submitting the final analysis for publication in a peer-reviewed medical journal. The open-label portion of the extension study will continue following participants over 96 weeks. 

The Alzheimer’s patients on ANAVEX®2-73 treatment demonstrated visible improvement during the 48 weeks, including reduced clinical declines as measured on the global functional and cognitive scales.  

Edward R Hammond, MD, PhD, MPH, Anavex’s CEO, said: “We are very pleased to see such positive clinical data in patients with Alzheimer’s disease, which is otherwise a progressive disease, thereby emphasizing the potentially significant implications these findings have for patients, caregivers, and healthcare systems worldwide,” 

Adding: 

“We intend to discuss these findings with regulatory authorities in the context of the ongoing clinical development of ANAVEX®2-73 in this indication, with the goal of providing a much-needed treatment to the millions of patients living with Alzheimer’s disease.”

*This is not investment advice. 

The Anavex Life Sciences (AVXL) stock price. 

The Anavex Life Sciences stock price rallied 67.31% to trade at $14.84, rising from Thursday’s closing price of $8.87. 


YOUR CAPITAL IS AT RISK. 81% OF RETAIL CFD ACCOUNTS LOSE MONEY.


Simon has over six years of professional trading experience across FX, commodities and equities. He has a strong passion for financial markets and is particularly focused on price action trading